The active ingredient in BSCT topical treatment is a polyclonal antibody directed towards Biosceptre’s novel proprietary cancer target, nf-P2X7.
Biosceptre expects to start clinical studies for BSCT at the end of 2012.
Biosceptre CEO Cliff Holloway said BSCT was initially developed as a proof of concept to validate their proprietary therapeutic cancer target, nf-P2X7.
"We are delighted that Silvercrest is providing the financial resources that will enable us to take this product through formal clinical evaluation for the benefit of the vast number of patients who are affected by these skin lesions, not just in Australia, but worldwide," Holloway said.